-
Je něco špatně v tomto záznamu ?
N-acetyl-D-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response
Krenek K., Kuldová M., Hulíková K., Stibor I., Lhoták P., Dudic M., Budka J., Pelantová H., Bezouska K., Fiserová A., Kren V.
Jazyk angličtina Země Nizozemsko
- MeSH
- acetylglukosamin analogy a deriváty farmakologie MeSH
- aktivace lymfocytů účinky léků MeSH
- buňky NK imunologie účinky léků MeSH
- financování organizované MeSH
- glykokonjugáty chemická syntéza terapeutické užití MeSH
- kalixareny chemie MeSH
- kinetika MeSH
- leukocyty mononukleární účinky léků MeSH
- lidé MeSH
- molekulární konformace MeSH
- molekulární modely MeSH
- nádory farmakoterapie imunologie MeSH
- protinádorové látky farmakologie chemická syntéza MeSH
- T-lymfocyty imunologie MeSH
- Check Tag
- lidé MeSH
A series of calixarenes substituted with 2-acetamido-2-deoxy-beta-D-glucopyranose linked by a thiourea spacer was prepared and tested for binding activity to heterogeneously expressed activation receptors of the rat natural killer cells NKR-P1, and the receptor CD69 (human NK cells, macrophages). In the case of NKR-P1, the binding affinity of beta-D-GlcNAc-substituted calixarenes carrying two or four sugar units was in a good agreement with the inhibitory potencies of the linear chitooligomers (chitobiose to chitotetraose) reported previously. The influence of GlcNAc substitution of the calixarene skeleton on binding affinity for CD69 receptor was more profound and the 5,11,17,23-tetrakis[N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-thioureido]-25,26,27,28-tetrapropoxycalix[4]arene (cone) (1) proved to be the best CD69 ligand identified to date. Lower GlcNAc substitution led to dramatic decrease of the binding activity (by about 1.5 order of magnitude per one GlcNAc unit). The immunostimulating activity results with the newly synthesized GlcNAc tetramers on calixarene scaffolds exhibited stimulation of natural cytotoxicity of human PBMC in concentrations 10(-4) and 10(-8)M. These calix-sugar compounds were superior to the previously tested PAMAM-GlcNAc(8)5.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10000963
- 003
- CZ-PrNML
- 005
- 20121003100925.0
- 008
- 100115s2007 ne e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Křenek, Karel $7 xx0122428
- 245 10
- $a N-acetyl-D-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response / $c Krenek K., Kuldová M., Hulíková K., Stibor I., Lhoták P., Dudic M., Budka J., Pelantová H., Bezouska K., Fiserová A., Kren V.
- 314 __
- $a Institute of Microbiology, Academy of Sciences of the Czech Republic, Vídenská 1083, 142 20 Praha 4, Czech Republic
- 520 9_
- $a A series of calixarenes substituted with 2-acetamido-2-deoxy-beta-D-glucopyranose linked by a thiourea spacer was prepared and tested for binding activity to heterogeneously expressed activation receptors of the rat natural killer cells NKR-P1, and the receptor CD69 (human NK cells, macrophages). In the case of NKR-P1, the binding affinity of beta-D-GlcNAc-substituted calixarenes carrying two or four sugar units was in a good agreement with the inhibitory potencies of the linear chitooligomers (chitobiose to chitotetraose) reported previously. The influence of GlcNAc substitution of the calixarene skeleton on binding affinity for CD69 receptor was more profound and the 5,11,17,23-tetrakis[N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-thioureido]-25,26,27,28-tetrapropoxycalix[4]arene (cone) (1) proved to be the best CD69 ligand identified to date. Lower GlcNAc substitution led to dramatic decrease of the binding activity (by about 1.5 order of magnitude per one GlcNAc unit). The immunostimulating activity results with the newly synthesized GlcNAc tetramers on calixarene scaffolds exhibited stimulation of natural cytotoxicity of human PBMC in concentrations 10(-4) and 10(-8)M. These calix-sugar compounds were superior to the previously tested PAMAM-GlcNAc(8)5.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a acetylglukosamin $x analogy a deriváty $x farmakologie $7 D000117
- 650 _2
- $a protinádorové látky $x farmakologie $x chemická syntéza $7 D000970
- 650 _2
- $a kalixareny $x chemie $7 D047250
- 650 _2
- $a glykokonjugáty $x chemická syntéza $x terapeutické užití $7 D006001
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buňky NK $x imunologie $x účinky léků $7 D007694
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a leukocyty mononukleární $x účinky léků $7 D007963
- 650 _2
- $a aktivace lymfocytů $x účinky léků $7 D008213
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární konformace $7 D008968
- 650 _2
- $a nádory $x farmakoterapie $x imunologie $7 D009369
- 650 _2
- $a T-lymfocyty $x imunologie $7 D013601
- 700 1_
- $a Kuldová, Markéta. $7 _AN042532
- 700 1_
- $a Hulíková, Katarína. $7 _AN043256
- 700 1_
- $a Stibor, Ivan, $d 1944- $7 mzk2004261066
- 700 1_
- $a Lhoták, Pavel $7 xx0064138
- 700 1_
- $a Dudič, Miroslav. $7 ntk2013789963
- 700 1_
- $a Budka, Jan $7 xx0125666
- 700 1_
- $a Pelantová, Helena $7 xx0141862
- 700 1_
- $a Bezouška, Karel, $d 1960- $7 jo2005273852
- 700 1_
- $a Fišerová, Anna $7 xx0074790
- 700 1_
- $a Křen, Vladimír $7 xx0070803
- 773 0_
- $w MED00001049 $t Carbohydrate research $g Roč. 342, č. 12-13 (2007), s. 1781-1792 $x 0008-6215
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20100114083259 $b ABA008
- 991 __
- $a 20121003101113 $b ABA008
- 999 __
- $a ok $b bmc $g 703691 $s 566132
- BAS __
- $a 3
- BMC __
- $a 2007 $b 342 $c 12-13 $d 1781-1792 $i 0008-6215 $m Carbohydrate research $x MED00001049
- LZP __
- $a 2010-b1/vtme